Updated results from the enfortumab vedotin phase 1 (EV-101) study in patients with metastatic urothelial cancer (mUC).

Jonathan E.  Rosenberg

Stock and Other Ownership Interests  - Illumina; Merck

Honoraria - AstraZeneca; Bristol-Myers Squibb; Medscape; Peerview; UpToDate; Vindico

Consulting or Advisory Role - Agensys; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; EMD Serono; Inovio Pharmaceuticals; Lilly; Merck; Roche/Genentech; Sanofi; Seagen

Research Funding - Agensys (Inst); Genentech (Inst); Genentech/Roche (Inst); Incyte; Mirati Therapeutics (Inst); Novartis (Inst); Oncogenex (Inst); Viralytics (Inst)

Patents, Royalties, Other Intellectual Property - Predictor of platinum sensitivity (Inst)

Travel, Accommodations, Expenses - Bristol-Myers Squibb; Genentech/Roche

Srikala S.  Sridhar

Consulting or Advisory Role - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Janssen (Inst); Roche/Genentech (Inst); Sanofi (Inst)

Research Funding - Bayer (Inst); Janssen (Inst); Sanofi (Inst)

Jingsong  Zhang

Honoraria - AstraZeneca/MedImmune; Bayer; Sanofi

Consulting or Advisory Role - AstraZeneca/MedImmune; Bayer; Sanofi

Speakers' Bureau - AstraZeneca/MedImmune; Sanofi

Research Funding - Astellas Medivation (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst)

David C.  Smith

Consulting or Advisory Role - Merck

Research Funding - Agensys (Inst); Astellas Pharma (Inst); Bayer (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb/Medarex (Inst); ESSA (Inst); Exelixis (Inst); Genentech (Inst); Incyte (Inst); Lilly (Inst); MedImmune (Inst); Medivation/Astellas (Inst); Merck (Inst); Millendo (Inst); Novartis (Inst); OncoMed (Inst); Seagen (Inst)

Joseph D.  Ruether

No Relationships to Disclose

Thomas W.  Flaig

Leadership - Aurora Oncology

Stock and Other Ownership Interests  - Aurora Oncology

Honoraria - BN ImmunoTherapeutics; GTx

Consulting or Advisory Role - GTX

Research Funding - Agensys; Aragon Pharmaceuticals; Astellas Pharma; astrazeneca/MedImmune; Bavarian Nordic; Bristol-Myers Squibb; Cougar Biotechnology; Dendreon; Exelixis; GTx; Janssen Oncology; La Roche-Posay; Lilly; Medivation; Novartis; Pfizer; Roche/Genentech; Sanofi; Seagen; Sotio; Tokai Pharmaceuticals

Patents, Royalties, Other Intellectual Property - The University of Colorado has filed 2 patents related in which I am an inventor. These are related to early-stage bladder cancer treatment and detection. Neither is commercialized or licensed at this time.

Travel, Accommodations, Expenses - Bavarian Nordic; GTx

Joaquina Celebre  Baranda

Employment - Halozyme

Stock and Other Ownership Interests  - Adaptimmune; Halozyme; Ignyta; Loxo

Research Funding - Novartis

Joshua Michael  Lang

Stock and Other Ownership Interests  - Salus Discovery

Consulting or Advisory Role - Sanofi; Sanofi

Research Funding - Agensys (Inst); Medivation (Inst); Novartis (Inst)

Patents, Royalties, Other Intellectual Property - I am listed on the patent on a technology for rare cell capture and analysis. This technology has been licensed by Salus Discovery, LLC though no commercial products are available.

Elizabeth R.  Plimack

Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; Clovis Oncology; Exelixis; Genentech/Roche; Horizon Pharma; Inovio Pharmaceuticals; Lilly; Merck Sharp & Dohme; Novartis; Pfizer

Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Merck Sharp & Dohme (Inst); Peloton Therapeutics (Inst); Pfizer (Inst)

Patents, Royalties, Other Intellectual Property - U.S. Patent No.: 14/588,503, Filed 1/2/2015. (Inst); US Patent No: 15/226,474 files on 7/1/15 (Inst)

Randeep S.  Sangha

Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Lundbeck; Merck; Pfizer; Roche

Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Lundbeck; Merck; Roche

Elisabeth I.  Heath

Honoraria - Bayer; Dendreon; Sanofi

Consulting or Advisory Role - Agensys

Speakers' Bureau - Sanofi

Research Funding - Agensys (Inst); Celgene (Inst); Celldex (Inst); Dendreon (Inst); Genentech/Roche (Inst); Inovio Pharmaceuticals (Inst); Millennium (Inst); Seagen (Inst); Tokai Pharmaceuticals (Inst)

Jaime R.  Merchan

Consulting or Advisory Role - Exelixis

Research Funding - Agensys; Lilly; Novartis; Rexahn Pharmaceuticals; Tocagen; TRACON Pharma

David I.  Quinn

Honoraria - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Dendreon; EMD Serono; Exelixis; Genentech/Roche; Janssen Oncology; Merck Serono; Merck Sharp & Dohme; Peloton Therapeutics; Pfizer; Piramal Life Science; Sanofi

Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Dendreon; Eisai; EMD Serono; Exelixis; Genentech/Roche; Janssen Oncology; Merck Sharp & Dohme; Peloton Therapeutics; Pfizer; Piramal Life Science; Sanofi

Research Funding - Genentech/Roche (Inst); GlaxoSmithKline (Inst); Millennium (Inst); Sanofi (Inst)

Sandy  Srinivas

Consulting or Advisory Role - Genentech/Roche

Speakers' Bureau - Genentech

Research Funding - Bristol-Myers Squibb (Inst); Genentech (Inst); Merck (Inst)

Matthew I.  Milowsky

Research Funding - Acerta Pharma (Inst); Agensys (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Merck (Inst); Pfizer (Inst); Roche/Genentech (Inst)

Travel, Accommodations, Expenses - Roche/Genentech

Chunzhang  Wu

Employment - Astellas Pharma

Elaina M.  Gartner

Employment - Seagen

Amal  Melhem-Bertrandt

No Relationships to Disclose

Daniel Peter  Petrylak

Stock and Other Ownership Interests  - Bellicum Pharmaceuticals; TYME

Consulting or Advisory Role - Bayer; Bellicum Pharmaceuticals; Dendreon; Exelixis; Ferring; Johnson & Johnson; Medivation; Millennium; Pfizer; Roche; Sanofi; TYME

Research Funding - Agensys; Astellas Medivation; AstraZeneca; Bayer; Dendreon; Endocyte; Genentech; Innocrin Pharma; Johnson & Johnson; Lilly; MedImmune; Merck; Millennium; Novartis; Oncogenex; Pfizer; Progenics; Roche; Sanofi; Seagen; Sotio

Expert Testimony - Celgene; sanofi